Lincoln Pharmaceuticals Limited — Results, 13-02-2025: Integrated Filing- Financial

Lincoln Pharmaceuticals Limited has announced a board meeting to review and approve the financial results for the quarter and nine months ended December 31, 2024. The company reported a standalone revenue from operations of ₹455.05 crore for the nine months, compared to ₹438.06 crore last fiscal. Net profit stood at ₹70.77 crore, down from ₹74.71 crore in the same period last year. EBITDA was reported at ₹104.13 crore, showing a slight decline. The company is focused on expanding its global footprint, targeting ₹750 crore in revenue by FY26 through new product registrations and geographic expansion, particularly in women's healthcare and dermatology. Overall, investors may perceive a positive outlook given the ongoing strategic initiatives and solid financial health.